Zoetis Inc., an animal health company, has completed a 19,000-square-foot, three-story expansion at its manufacturing facility in Lincoln, Nebraska. Zoeits was spun off in 2013 from Pfizer as a separate, independent publicly traded animal health company. Zoetis is headquartered in Florham Park, New Jersey.

The Lincoln site is one of the largest internal manufacturing operations within Zoetis, employing approximately 500 people. With the expansion, as many as 30 new positions could be added at peak production time. Zoetis produces some of its flagship pharmaceutical products and vaccines at the Lincoln plant, including Bovi-Shield Gold and Respisure One for livestock and Riamadyl (carprofen) for dogs. The expansion will also facilitate the full production of Synovex, a product that helps increase weight gain and improve feed efficiency in beef cattle.

Zoetis' most recent products produced in Lincoln include: Canine Atopic Dermatitis Immunotherapeutic, an antibody therapy that targets interleukin-31 (IL-31) to help reduce clinical signs associated with atopic dermatitis in dogs, as well as a vaccine to help fight porcine epidemic diarrhea virus, an emerging disease that devastated U.S. pig farms in recent years. Both products are conditionally licensed by the U.S. Department of Agriculture.

Source: Zoetis